TY - JOUR

T1 - A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis

T2 - Ineffectiveness in head‐and‐neck dermatitis

AU - Vittrup, Ida

AU - Krogh, Niels Steen

AU - Larsen, Henrik Hedegaard Pliess

AU - Elberling, Jesper

AU - Skov, Lone

AU - Ibler, Kristina Sophie

AU - Jemec, Gregor B. E.

AU - Mortz, Charlotte G.

AU - Bach, Rasmus Overgaard

AU - Bindslev‐jensen, Carsten

AU - Dalager, Maiken Glud

AU - Egeberg, Alexander

AU - Agner, Tove

AU - Deleuran, Mette

AU - Vestergaard, Christian

AU - Thyssen, Jacob Pontoppidan

PY - 2023

Y1 - 2023

N2 - BackgroundEvaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.ObjectivesTo examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.MethodsWe included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017–2022.ResultsAt all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6–25.2), at week 4: 6.5 (3.5–11.6), at week 16: 3.7 (1.2–6.2), at week 52: 2.0 (0.8–3.6), at week 104: 1.7 (0.8–3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.ConclusionsWhile 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

AB - BackgroundEvaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.ObjectivesTo examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.MethodsWe included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017–2022.ResultsAt all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6–25.2), at week 4: 6.5 (3.5–11.6), at week 16: 3.7 (1.2–6.2), at week 52: 2.0 (0.8–3.6), at week 104: 1.7 (0.8–3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.ConclusionsWhile 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

U2 - 10.1111/jdv.18849

DO - 10.1111/jdv.18849

M3 - Journal article

C2 - 36606551

VL - 37

SP - 1046

EP - 1055

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0929-0168

IS - 5

ER -